This post hoc analysis of a phase 2 study found that ropeginterferon alfa-2b elicited a reduction in HCT values, WBC counts, PLT counts, and JAK2 V617F allele burden in Japanese patients with low-risk PV. This evidence concerns the gene JAK2 and acquired polycythemia vera.